Company Overview and News

 
Rolta India Limited - Reply to Clarification Sought

2018-10-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RTI RLTAY 82HP 500366 ROLTA

 
Rolta India Limited - Clarification

2018-09-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RTI RLTAY 82HP 500366 ROLTA

 
Rolta India Limited - Updates

2018-09-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RTI RLTAY 82HP 500366 ROLTA

 
D-Street Buzz: IT, pharma stocks up on weak rupee led by Aurobindo Pharma, HCL Tech; RIL gains

2018-09-25 moneycontrol
There is no stopping the slide in the Indian stock market as the benchmark indices have yet again opened lower amid higher crude oil prices and a falling rupee. The Nifty50 is down 48 points and is trading below 11,ooo at 10,919 while the Sensex is trading lower by 119 points at 36,185.
523768 ESL RTI RLTAY 500325 82HP TCHQY 532636 IIFL 532832 532755 539437 531795 535789 532121 SONATSOFTW BJJQY GAILF EICHERMOT RLNIY GRUH AXB 524804 511072 JETAIRWAYS CANFINHOME YYBKY 511196 TECHM AXBA DHFL BAJFINANCE TATASTEEL TATLY GAILY KOTAKBANK VSTIND IBREALEST AUROPHARMA GUJBOROS 539254 RELIANCE 532617 532215 511288 505200 509966 532221 500470 532187 IDFCBANK AXISBANK ENGINERSIN RIGD 500034 ADANITRANS YESBANK ECQRY INDUSINDBK KMBKY IDKQY ATULAUTO 533264 532648 GRHFY AXBKY IBULHSGFIN 532178 TTST ARBQY 500366 500247 ROLTA DENABANK

 
Rolta India Limited - Shareholders meeting

2018-09-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RTI RLTAY 82HP 500366 ROLTA

 
Rolta India Limited - Shareholders meeting

2018-09-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RTI RLTAY 82HP 500366 ROLTA

 
BSE revises circuit limit of J L Morison, 5 others

2018-09-20 moneycontrol
Leading exchange BSE has revised the circuit limit for the shares of FMCG firm J L Morison (India) and five other companies to curb excessive volatility in their prices. The new limits, effective Friday, will ensure stock prices do not fluctuate beyond a prescribed level during a session.
RTI RLTAY 82HP ECORECO 500366 RAJOOENG 530643 ROLTA 522257

1
Military Communications Market worth $37.67 Bn by 2023

2018-08-22 asdnews
The report, now available on ASDReports, "Military Communications Market by Communication Type (Airborne, Air-Ground, Underwater, Ground-Based), Component (Military Satcom Systems, Military Radio Systems, Military Security Systems), Application, End User, and Region - Global Forecast to 2023", The military communications market is expected to grow from USD 31.50 billion in 2018 to USD 37.67 billion by 2023, at a compound annual growth rate (CAGR) of 3.
ESLT BAESY LMT RTI RLTAY GD 82HP IRDDA COL BAESF IRIIZ NOC IRDMB 500366 BA HRS ROLTA IRDM

 
Rolta India Limited - Press Release

2018-08-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
RTI RLTAY 82HP 500366 ROLTA

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...